Post-Market Studies May Be "Least Burdensome" Alternative - Industry
This article was originally published in The Gray Sheet
Executive Summary
FDA should consider postmarket controls for breakthrough devices as an alternative to randomized, controlled clinical studies as a "least burdensome" route to approval, a pan-industry task force suggests in Nov. 24 comments on FDA's draft guidance.